Pierre Fabre Medicament

This phase 2 trial tested a combination of three drugs—encorafenib, binimetinib, and cetuximab—in 95 patients with a specific type of advanced colorectal cancer (BRAF V600E mutation) who had not received prior treatment for their metastatic disease. The goal was to see how many p…

This study tested a new two-drug combination (encorafenib and cetuximab) against standard treatments in 107 Chinese patients with a specific genetic mutation (BRAF V600E) that makes colorectal cancer harder to treat. The goal was to see if the new combo could slow cancer growth b…

This study involved 155 women with early breast cancer who had been taking hormone therapy for 2-3 years. Researchers wanted to understand how skin-related side effects from the treatment impact their quality of life. Participants filled out questionnaires about their skin sympto…

This study followed about 400 adults with advanced BRAF-mutant melanoma who were taking targeted therapy (BRAF/MEK inhibitors) and using a smartphone app called TavieSkin. The goal was to describe patient characteristics, how they used the app, their quality of life, and treatmen…

This study looked back at medical records of 274 people with a specific type of advanced colorectal cancer (BRAF V600E mutation) to see what treatments they received and how well they worked. The goal was to understand real-world treatment patterns and outcomes, since there is no…

This study reviewed medical records of 111 adults with early-stage HER2-positive breast cancer who received the drug neratinib after their initial treatment. The goal was to describe their age, gender, health conditions, and tumor details. This was an observational study, meaning…